Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Q2 Results 2026 (FY27): Revenue ₹7,793 Cr, PAT ₹925 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and fundraising.
Dr Reddys Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ.
As stated in Dr Reddys Laboratories Ltd's Q2 FY27 investor presentation · published 23 Oct 2026. Reported figures, not investment advice.
Based on Dr Reddys Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). EBITDA for Q2FY27: ₹1,783 Cr with a margin of 20.6%, up 24% YoY and 77% QoQ.
From Dr Reddys Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 23 Oct 2026.
Revenue & Sales Performance
- Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4).
- Global Generics revenue: ₹7,793 Cr, up 0.7% YoY and 8% QoQ (Page 7).
- PSAI revenue: ₹831 Cr, up 12% YoY and 2% QoQ (Page 13).
- North America revenue: ₹2,489 Cr, up 23% YoY and 13% QoQ (Page 9).
- Europe revenue: ₹1,393 Cr, up 1% YoY and 3% QoQ (Page 12).
- India revenue: ₹1,851 Cr, up 17% YoY and 8% QoQ (Page 11).
- Emerging Markets revenue: ₹2,059 Cr, up 24% YoY and 12% QoQ (Page 10).
- Volume impact noted: Lower API volume offtake impacting PSAI growth (Page 13).
2 more points from Dr Reddys Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
- EBITDA for Q2FY27: ₹1,783 Cr with a margin of 20.6%, up 24% YoY and 77% QoQ.
- Operating margin (EBITDA margin) reported at 20.6% for Q2FY27.
- Profit after tax (PAT) for Q2FY27: ₹925 Cr, up 36% YoY and 109% QoQ.
2 more points from Dr Reddys Laboratories Ltd's call on margins
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
- On Page 8, the presentation shows the trend in Net Debt/Equity ratio and states a net surplus adjusted for non-current cash & borrowings of ₹2,502 Cr as of 30 September 2026, indicating a net cash position rather than increased borrowings.
- There is no explicit mention of new fundraising through debt or equity in the presentation.
- The net debt/equity ratio improved slightly from -0.08/-0.09 in earlier quarters to -0.06 in Q2FY27, signaling lower net debt or higher cash surplus.
- The company has maintained a healthy financial position with net cash surplus, but no announcements on raising new debt or equity financing are included in this document.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Dr Reddys Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q2 FY27)
4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect
- Sakar Healthcare Ltd (Q2 FY27)
2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Bajaj Healthcare Ltd (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Arthneeti Pro · Annual
Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Reddys Laboratories Ltd Q2 FY27 results?
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). EBITDA for Q2FY27: ₹1,783 Cr with a margin of 20.6%, up 24% YoY and 77% QoQ.
What is Dr Reddys Laboratories Ltd share price analysis?
Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 32.1 with a market cap of ₹103,459 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddys Laboratories Ltd planning capital expenditure?
The presentation does not provide specific details on capital expenditure related to capacity expansion or new plants/projects, amounts allocated, statuses, or timelines.
Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.